Cerebral Protection in TAVR-Can We Do Without? A Real-World All-Comer Intention-to-Treat Study-Impact on Stroke Rate, Length of Hospital Stay, and Twelve-Month Mortality.

Moreover, all three studies failed to show a reduction in clinically relevant cerebrovascular event rate with SentinelTM, although a strong trend was shown in the SENTINEL trial (5.6% vs. 9.1%, p = 0.25).

also in 5,725 other papers

In the two other studies, a trend towards a reduction in lesion volume with SentinelTM was shown, which failed to reach statistical significance–potentially due to limited patient numbers (Sentinel trial: 121 treated with CPS [ 10 ]; MISTRAL-C: 32 treated with CPS [ 11 ]).

also in 6,035 other papers